ARVINAS INC (ARVN)

Balfour Capital Group Researched ARVINAS INC
 on February 1st, 2024.

Arvinas is singularly focused on developing new options for patients in need, pioneering a new class of medicines to target and degrade disease-related proteins. For people living with cancers and other difficult-to-treat diseases, their approach has the potential to be transformative.

Post Recommendation Price Trend Chart The chart's commencement marks the instance of our stock recommendation.

Track all markets on TradingView
  • We have established a Buy recommendation at $45.65 on February 1st, 2024.
  • Our designated price target stands at $150.00

Analysts Research

With steadfast dedication to thorough research, Balfour Capital Group engages with esteemed analysts and companies, evident below, to amplify and elevate our proficiency. This collaborative approach enriches our findings, granting readers and researchers a profound comprehension of the rationale behind our recommendations and research objectives.

COMPANY SNAPSHOT

Balfour Capital Group's precise and thorough research crafted by our team of analysts.

COMPANY SNAPSHOT

VIEW MORE

ARGUS ANALYST

Argus Analyst Notes offers timely investment recommendations, insights.

ARGUS ANALYST

VIEW MORE

ARGUS QUANTITIVE

Argus Quantitative analyzes energy, commodities, and finance with data analytics

ARGUS QUANTITIVE

VIEW MORE

THOMSON REUTERS

Thomson Reuters delivers global financial, legal, and business information to professionals.

THOMSON REUTERS

VIEW MORE

MORGAN STANLEY

Morgan Stanley researches industries, offers insights to clients.

MORGAN STANLEY

VIEW MORE
ARVN

2023 Q3 EARNING REPORT

A Q3 report evaluates company financials for investors

EARNINGS REPORT

VIEW MORE

Balfour Capital Group wants to clarify that our recommendation to Buy ARVINAS INC
(ARVN) is based on thorough research conducted by our dedicated teams.

We invest significant time and resources in analyzing market trends, financial data, and industry insights to provide well-informed guidance.
However, it is important to note that our recommendation does not guarantee any specific financial outcomes. The decision to act on our recommendation should be made at your discretion. Please be aware that investments carry inherent risks, and the value of investments can fluctuate, potentially resulting in financial loss.

*THIS INFORMATION IS PROVIDED FOR COMMERCIAL AND INDICATIVE PURPOSES ONLY AND MAY DIFFER FROM REALITY. PAST PERFORMANCE IS NOT INDICATIVE OF FUTURE RESULTS. TRADING WITH LEVERAGE INVOLVES A SUBSTANTIAL RISK OF LOSS AND MAY NOT BE SUITABLE FOR ALL INVESTORS.*